WD Rutherford LLC Has $339,000 Stake in Edwards Lifesciences Co. (NYSE:EW)

WD Rutherford LLC reduced its position in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 49.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,785 shares of the medical research company's stock after selling 4,697 shares during the period. WD Rutherford LLC's holdings in Edwards Lifesciences were worth $339,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Crowley Wealth Management Inc. acquired a new stake in Edwards Lifesciences in the 4th quarter valued at $26,000. Vega Investment Solutions bought a new position in shares of Edwards Lifesciences in the 4th quarter valued at about $27,000. Millstone Evans Group LLC bought a new position in shares of Edwards Lifesciences in the 4th quarter valued at about $29,000. Park Square Financial Group LLC acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at about $44,000. Finally, Catalyst Capital Advisors LLC bought a new stake in Edwards Lifesciences during the fourth quarter worth about $54,000. 79.46% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. Canaccord Genuity Group raised their price target on Edwards Lifesciences from $71.00 to $75.00 and gave the company a "hold" rating in a research note on Friday, April 25th. Citigroup reiterated a "buy" rating and set a $95.00 price objective (up previously from $84.00) on shares of Edwards Lifesciences in a research note on Thursday, May 22nd. Robert W. Baird raised their target price on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the company a "neutral" rating in a research note on Thursday, April 24th. Piper Sandler boosted their target price on shares of Edwards Lifesciences from $80.00 to $83.00 and gave the stock an "overweight" rating in a report on Tuesday, May 13th. Finally, Truist Financial dropped their price target on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a research report on Friday, April 11th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of "Hold" and a consensus target price of $80.20.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $74.80 on Tuesday. The stock has a 50 day simple moving average of $74.70 and a 200 day simple moving average of $72.96. The stock has a market cap of $43.88 billion, a P/E ratio of 10.73, a PEG ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $95.25. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, topping analysts' consensus estimates of $0.60 by $0.04. The company had revenue of $1.41 billion during the quarter, compared to the consensus estimate of $1.40 billion. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The company's revenue was up 6.2% on a year-over-year basis. During the same quarter last year, the firm earned $0.66 earnings per share. Research analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Insiders Place Their Bets

In related news, CFO Scott B. Ullem sold 11,250 shares of the business's stock in a transaction dated Wednesday, March 26th. The stock was sold at an average price of $70.87, for a total value of $797,287.50. Following the completion of the transaction, the chief financial officer now owns 30,387 shares of the company's stock, valued at $2,153,526.69. The trade was a 27.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of the company's stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $69.81, for a total transaction of $663,195.00. Following the sale, the vice president now directly owns 47,206 shares of the company's stock, valued at $3,295,450.86. This represents a 16.75% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 51,898 shares of company stock worth $3,796,154 in the last quarter. Corporate insiders own 1.29% of the company's stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.